Appointment dossier — Glioblastoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Glioblastoma
- Temozolomide — Human evidence · 2 positive / 1 negative-mixed · PMID 40466642, 36067704, 38672566, 38630257
- Pembrolizumab — Human evidence · 1 positive · PMID 40466642
- Bevacizumab — Review evidence · 0 positive / 1 negative-mixed · PMID 35806212, 26664126
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05669820 · Phase 2 / Phase 3 — Antisecretory Factor Glioblastoma Phase 2 (Sweden)
- NCT07021339 · Phase 3 — Anterior Temporal Lobectomy in Temporal Glioblastoma (Germany)
- NCT05902169 · Phase 3 — Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM (United States)
- NCT06558214 · Phase 2 — OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial (United States)
- NCT06011109 · Phase 1 / Phase 2 — Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab (United States)
- NCT07285044 · Phase 2 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (United States)
- NCT06805305 · Phase 2 — DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) (United States)
- NCT05843253 · Phase 2 — Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant (United States)
- NCT05052957 · Phase 2 — hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (United States)
- NCT07185880 · Phase 1 / Phase 2 — A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients (United States)
- NCT01269853 · Phase 1 / Phase 2 — Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA (United States)
- NCT06672575 · Phase 1 / Phase 2 — A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma (United States)
- NCT05083754 · Phase 1 — Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma (United States)
- NCT05106296 · Phase 1 — Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer (United States)
- NCT07551336 · Phase 1 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma (China)
- NCT07493447 · Early Phase 1 — Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures (United States)
- NCT06782984 — Drug Response Testing and Repurposing Using Glioblastoma Organoid (South Korea)
- NCT06222138 — Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma (France)
Most-relevant first: trials that name Glioblastoma, then broader trials you may still qualify for. 324 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Temozolomide has been studied in people for Glioblastoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Pembrolizumab has been studied in people for Glioblastoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT05669820), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?